Logo image of SMTI

SANARA MEDTECH INC (SMTI) Stock Fundamental Analysis

USA - NASDAQ:SMTI - US79957L1008 - Common Stock

28.26 USD
-1.04 (-3.55%)
Last: 10/17/2025, 8:00:02 PM
28.6 USD
+0.34 (+1.2%)
After Hours: 10/17/2025, 8:00:02 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to SMTI. SMTI was compared to 191 industry peers in the Health Care Equipment & Supplies industry. SMTI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, SMTI is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

SMTI had negative earnings in the past year.
SMTI had a positive operating cash flow in the past year.
SMTI had negative earnings in each of the past 5 years.
In the past 5 years SMTI always reported negative operating cash flow.
SMTI Yearly Net Income VS EBIT VS OCF VS FCFSMTI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2M -4M -6M -8M -10M

1.2 Ratios

The Return On Assets of SMTI (-10.06%) is better than 60.73% of its industry peers.
With a Return On Equity value of -28.08%, SMTI perfoms like the industry average, outperforming 56.54% of the companies in the same industry.
Industry RankSector Rank
ROA -10.06%
ROE -28.08%
ROIC N/A
ROA(3y)-9.93%
ROA(5y)-19.18%
ROE(3y)-17.7%
ROE(5y)-29.97%
ROIC(3y)N/A
ROIC(5y)N/A
SMTI Yearly ROA, ROE, ROICSMTI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100

1.3 Margins

SMTI has a better Gross Margin (91.76%) than 98.43% of its industry peers.
SMTI's Gross Margin has been stable in the last couple of years.
SMTI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.76%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.07%
GM growth 5Y0.2%
SMTI Yearly Profit, Operating, Gross MarginsSMTI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

More info and screens

4

2. Health

2.1 Basic Checks

SMTI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SMTI has more shares outstanding
Compared to 5 years ago, SMTI has more shares outstanding
SMTI has a worse debt/assets ratio than last year.
SMTI Yearly Shares OutstandingSMTI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
SMTI Yearly Total Debt VS Total AssetsSMTI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

An Altman-Z score of 2.88 indicates that SMTI is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.88, SMTI is doing good in the industry, outperforming 67.02% of the companies in the same industry.
The Debt to FCF ratio of SMTI is 1277.94, which is on the high side as it means it would take SMTI, 1277.94 years of fcf income to pay off all of its debts.
SMTI's Debt to FCF ratio of 1277.94 is fine compared to the rest of the industry. SMTI outperforms 65.44% of its industry peers.
SMTI has a Debt/Equity ratio of 1.25. This is a high value indicating a heavy dependency on external financing.
SMTI's Debt to Equity ratio of 1.25 is on the low side compared to the rest of the industry. SMTI is outperformed by 79.58% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.25
Debt/FCF 1277.94
Altman-Z 2.88
ROIC/WACCN/A
WACC8.48%
SMTI Yearly LT Debt VS Equity VS FCFSMTI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M 40M

2.3 Liquidity

A Current Ratio of 2.26 indicates that SMTI has no problem at all paying its short term obligations.
With a Current ratio value of 2.26, SMTI perfoms like the industry average, outperforming 43.46% of the companies in the same industry.
A Quick Ratio of 2.03 indicates that SMTI has no problem at all paying its short term obligations.
SMTI has a Quick ratio (2.03) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.26
Quick Ratio 2.03
SMTI Yearly Current Assets VS Current LiabilitesSMTI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

6

3. Growth

3.1 Past

SMTI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -48.97%.
Looking at the last year, SMTI shows a very strong growth in Revenue. The Revenue has grown by 34.30%.
Measured over the past years, SMTI shows a very strong growth in Revenue. The Revenue has been growing by 49.08% on average per year.
EPS 1Y (TTM)-48.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.9%
Revenue 1Y (TTM)34.3%
Revenue growth 3Y53.13%
Revenue growth 5Y49.08%
Sales Q2Q%28.14%

3.2 Future

Based on estimates for the next years, SMTI will show a very strong growth in Earnings Per Share. The EPS will grow by 36.86% on average per year.
SMTI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.14% yearly.
EPS Next Y12.32%
EPS Next 2Y24.6%
EPS Next 3Y36.86%
EPS Next 5YN/A
Revenue Next Year22.74%
Revenue Next 2Y18.51%
Revenue Next 3Y16.14%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
SMTI Yearly Revenue VS EstimatesSMTI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
SMTI Yearly EPS VS EstimatesSMTI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 0.5 -0.5 -1

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

SMTI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SMTI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SMTI Price Earnings VS Forward Price EarningsSMTI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

SMTI's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. SMTI is cheaper than 62.83% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, SMTI is valued a bit cheaper than 65.44% of the companies in the same industry.
Industry RankSector Rank
P/FCF 7269.19
EV/EBITDA 143.22
SMTI Per share dataSMTI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

SMTI's earnings are expected to grow with 36.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.6%
EPS Next 3Y36.86%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SMTI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SANARA MEDTECH INC

NASDAQ:SMTI (10/17/2025, 8:00:02 PM)

After market: 28.6 +0.34 (+1.2%)

28.26

-1.04 (-3.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-13 2025-08-13/bmo
Earnings (Next)11-12 2025-11-12
Inst Owners12.55%
Inst Owner Change-0.67%
Ins Owners8.78%
Ins Owner Change0.26%
Market Cap251.51M
Analysts82.5
Price Target51 (80.47%)
Short Float %7.1%
Short Ratio6.55
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)34.38%
Min EPS beat(2)20.02%
Max EPS beat(2)48.75%
EPS beat(4)3
Avg EPS beat(4)15.39%
Min EPS beat(4)-53.45%
Max EPS beat(4)48.75%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.72%
Min Revenue beat(2)-2.13%
Max Revenue beat(2)0.69%
Revenue beat(4)2
Avg Revenue beat(4)0.29%
Min Revenue beat(4)-2.13%
Max Revenue beat(4)2.64%
Revenue beat(8)4
Avg Revenue beat(8)-1.06%
Revenue beat(12)5
Avg Revenue beat(12)-2.89%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2.04%
EPS NQ rev (1m)0%
EPS NQ rev (3m)45.57%
EPS NY rev (1m)0%
EPS NY rev (3m)37.18%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.3%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.46%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.59
P/FCF 7269.19
P/OCF 68.88
P/B 7.11
P/tB N/A
EV/EBITDA 143.22
EPS(TTM)-1.16
EYN/A
EPS(NY)-0.51
Fwd EYN/A
FCF(TTM)0
FCFY0.01%
OCF(TTM)0.41
OCFY1.45%
SpS10.93
BVpS3.98
TBVpS-1.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.06%
ROE -28.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.76%
FCFM 0.04%
ROA(3y)-9.93%
ROA(5y)-19.18%
ROE(3y)-17.7%
ROE(5y)-29.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.07%
GM growth 5Y0.2%
F-Score4
Asset Turnover0.98
Health
Industry RankSector Rank
Debt/Equity 1.25
Debt/FCF 1277.94
Debt/EBITDA 21.41
Cap/Depr 73.04%
Cap/Sales 3.72%
Interest Coverage N/A
Cash Conversion 176.83%
Profit Quality N/A
Current Ratio 2.26
Quick Ratio 2.03
Altman-Z 2.88
F-Score4
WACC8.48%
ROIC/WACCN/A
Cap/Depr(3y)14.51%
Cap/Depr(5y)146.81%
Cap/Sales(3y)0.77%
Cap/Sales(5y)3.19%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-48.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.9%
EPS Next Y12.32%
EPS Next 2Y24.6%
EPS Next 3Y36.86%
EPS Next 5YN/A
Revenue 1Y (TTM)34.3%
Revenue growth 3Y53.13%
Revenue growth 5Y49.08%
Sales Q2Q%28.14%
Revenue Next Year22.74%
Revenue Next 2Y18.51%
Revenue Next 3Y16.14%
Revenue Next 5YN/A
EBIT growth 1Y32.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y100.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y163.61%
OCF growth 3YN/A
OCF growth 5YN/A